Abstract:OATP1B1 and OATP1B3 are two important drug uptake transporters expressed in human hepatocytes. They mediate the uptake of numerous drugs and other compounds and multiple inhibitors have been identified. However, it has also been suggested that these inhibitors may act as substrates for OATPs. Therefore, we wanted to establish the competitive counterflow assay described by Harper and Wright ( Am J Physiol Renal Physiol 2013; 304:F56–67 ) for OATP1B1 and OATP1B3 with the model substrate estradiol‐17β‐glucuronide (E17βG). This assay should allow to identify compounds that are able to exchange for an OATP substrate such as [ 3 H]‐E17βG that was used to preload OATP expressing CHO cells. CHO cells stably expressing either OATP1B1 or OATP1B3 were used and time dependent uptake of 10nM [ 3 H]‐E17βG was determined on 96‐well plates. Uptake reached a steady‐state plateau at 2 hours and addition of unlabeled E17βG to the extracellular medium at this time triggered time and concentration dependent efflux of [ 3 H]‐E17βG from the preloaded cells, indicating that extracellular E17βG exchanged for intracellular [ 3 H]‐E17βG. This assay was then used to test whether several known OATP substrates would also lead to [ 3 H]‐E17βG efflux, indicating that they are exchanged for the intracellular substrate. After preloading the cells with [ 3 H]‐E17βG, addition of known substrates such as E17βG, estrone‐3‐sulfate, bromosulfophthalein, taurocholate, and rifampicin to the extracellular medium indeed resulted in [ 3 H]‐E17βG efflux, confirming that OATP1B1 and OATP1B3 handle their substrates as exchangers. As negative controls we used glucose, glutamic acid, ouabain and metformin which did not result in [ 3 H]‐E17βG efflux. We then began testing known OATP inhibitors to see whether they would trigger [ 3 H]‐E17βG efflux, and thus would be OATP substrates. Among the tested inhibitors, many resulted in [ 3 H]‐E17βG efflux from both OATP1B1 and OATP1B3 expressing CHO cells, and thus seem to be substrates. These included bromocryptine, cyclosporine A, DIDS, indomethacin, ketoconazole, reserpine, and salinomycin. A few, including berberine, erythromycin, gliquidone, nifedipine, and paranitrosaniline seem to be substrates only for OATP1B1. Thus, because the tested substrates do not need to be radiolabeled and the CCF assay can be performed on 96‐well plates, this is a good screening tool to identify OATP inhibitors that are transported substrates. Support or Funding Information This work was supported by the National Institute of Health Grants R01‐GM077335 and P20‐GM103549‐07.

Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow Screen

Using a competitive counterflow assay to identify novel cationic substrates of OATP1B1 and OATP1B3

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors

Establishing the Competitive Counterflow Assay for OATP1B1 and OATP1B3

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors

Discovery of Potent, Orally Active Compounds of Tyrosine Kinase and Serine/Threonine-Protein Kinase Inhibitor with Anti-Tumor Activity in Preclinical Assays

Novel Mechanism of Impaired Function of Organic Anion-Transporting Polypeptide 1B3 in Human Hepatocytes: Post-Translational Regulation of OATP1B3 by Protein Kinase C Activation

High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3

Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

Analysis of amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter organic anion transporting polypeptide 1B1 (OATP1B1)

Organic anion transporting polypeptide 2B1 (OATP2B1), an expanded substrate profile, does it align with OATP2B1’s hypothesized function?

Identification of Novel Small-Molecule Inhibitors for Human Transketolase by High-Throughput Screening with Fluorescent Intensity (FLINT) Assay

Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes

Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib

Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors

A novel flow cytometric HTS assay reveals functional modulators of ATP binding cassette transporter ABCB6

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines

In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1

A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier

Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates